Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 71.45

+2.8%

Nov 10 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (684)	7/31/2006 1:04:31 PM
From: Jibacoa	Read Replies (2) of 3722

As previously mentioned on my post to Peter in February, RGEN's CEO Walter Herlihy made reference to the patent claims pending against BMY & IMCL in his letter to the shareholders. The patent claim against BMY is the one that Peter had mentioned, but the one that made today's spike on RGEN is the one against IMCL. RGEN's claim pattern against BMY is concerning methods for using CTLA4-Ig for treating RA based on US Patent No.6,685,941 which it owns together with Michigan Univ. & has to do with BMY's application for Orencia. On Friday the USA District Court in Massachusetts issued a Summary Judgment ruling in favor of RGEN & MIT in the patent lawsuit over the production of Erbitux. Patent 4,663,281 covers genetic elements that increase protein production in a mammalian cell, & IMCL reported that it had produced approximately $1B worth of Erbitux & BMY paid IMCL $900M as well as a 39% royalty on the net sales of Erbitux in the US. ( So it is possible that this was the patent that Peter was interested concerning BMY. <g>) At any rate, RGEN traded as high as $3.40 at 11.50AM & still is up 25% for the day on volume of 590,190 bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next